

Valeria Ricciari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5987982/publications.pdf>

Version: 2024-02-01

215
papers

13,200
citations

31902

53
h-index

24179

110
g-index

224
all docs

224
docs citations

224
times ranked

11217
citing authors

#	ARTICLE	IF	CITATIONS
1	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 240-250.	2.9	6
2	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022, 61, 4384-4396.	0.9	10
3	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	0.9	20
4	Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization. <i>Biomedicines</i> , 2022, 10, 6.	1.4	6
5	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	0.9	7
6	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	0.9	20
7	Subclinical atherosclerosis in systemic sclerosis: Different risk profiles among patients according to clinical manifestations. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 502-509.	0.9	5
8	COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort. <i>Clinical Rheumatology</i> , 2021, 40, 1393-1397.	1.0	6
9	<i>Helicobacter pylori</i> and Upper Endoscopy in Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 40-41.	0.5	0
10	Complementary Effects of Carbamylated and Citrullinated LL37 in Autoimmunity and Inflammation in Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1650.	1.8	11
11	SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 953-954.	0.5	62
12	New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis. <i>Antibodies</i> , 2021, 10, 12.	1.2	8
13	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2894.	1.8	9
14	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	2.2	25
15	OP0246â€¦PREDICTIVE VALUE OF LABORATORY AND INSTRUMENTAL FINDINGS IN THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS. ROLE FOR CXCL4 CHEMOKINE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 150.2-151.	0.5	0
16	POS1185â€¦IMPACT OF LOCKDOWN DURING COVID-19 PANDEMIC ON THE ONSET OF POST-TRAUMATIC STRESS DISORDER (PTSD) IN SYSTEMIC SCLEROSIS PATIENTS: A CASE-CONTROL STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 873.2-874.	0.5	0
17	POS0321â€¦USE OF HYDROXYCHLOROQUINE AND SYSTEMIC SCLEROSIS: RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY ON THE EUSTAR COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 387.3-388.	0.5	0
18	POS0317â€¦THE PERFORMANCE OF DIFFUSING CAPACITY FOR MONOXIDE CARBON (DLCO) AND FORCED VITAL CAPACITY (FVC) IN PREDICTING THE ONSET OF SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD) IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) DATABASE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 385-386.	0.5	0

#	ARTICLE	IF	CITATIONS
19	POS0433â€¦CAN INTERLEUKIN 33 (IL-33) BE CONSIDERED A VALUABLE BIOMARKER IN THE EARLY STAGES OF SYSTEMIC SCLEROSIS? ANALYSIS OF A MONOCENTRIC COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 445.2-445.	0.5	0
20	POS1240â€¦HYDROXYCHLOROQUINE CARDIOTOXICITY: A CASE-CONTROL STUDY COMPARING PATIENTS WITH COVID19 AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 903.1-903.	0.5	1
21	POS0861â€¦EFFECTIVENESS AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROPENSITY SCORE CONTROL MATCHED OBSERVATIONAL STUDY OF THE EUSTAR COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 685-686.	0.5	0
22	AB0234â€¦SURVIVAL OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS: A REAL-LIFE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1143.1-1143.	0.5	0
23	POS1246â€¦COVID-19 IN ITALIAN PATIENTS WITH RHEUMATIC AUTOIMMUNE SYSTEMIC DISEASES: RESULTS OF A NATIONWIDE SURVEY STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 906-907.	0.5	0
24	POS1219â€¦SARS-COV-2 VACCINE HESITANCY AMONG PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A MESSAGE FOR RHEUMATOLOGISTS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 893.1-893.	0.5	1
25	Response to: â€œCorrespondence on â€œSARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologistsâ€™â€™ by Smerilli <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e169-e169.	0.5	2
26	Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments. <i>Current Pharmaceutical Design</i> , 2021, 27, 4245-4252.	0.9	12
27	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	2.5	231
28	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	0.9	14
29	An exploratory cross-sectional study of subclinical vascular damage in patients with polymyalgia rheumatica. <i>Scientific Reports</i> , 2020, 10, 11407.	1.6	2
30	Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5102.	1.8	26
31	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. <i>Arthritis Research and Therapy</i> , 2020, 22, 127.	1.6	18
32	ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisisâ€”a EUSTAR analysis. <i>Arthritis Research and Therapy</i> , 2020, 22, 59.	1.6	38
33	Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2020, 10, 5851.	1.6	27
34	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.5	71
35	FRI0575â€¦BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIQUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 890-891.	0.5	1
36	OPO249â€¦LONG-TERM EXTENSION RESULTS OF RISE-SSC, A RANDOMIZED TRIAL OF RIOCIQUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 156.2-157.	0.5	3

#	ARTICLE	IF	CITATIONS
37	FRIO239â€¦ANTI-NXP2 ANTIBODIES: CLINICAL AND SEROLOGICAL ASSOCIATIONS IN A MULTICENTRIC ITALIAN STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 703.1-704.	0.5	0
38	SAT0555â€¦MUSCULOSKELETAL ULTRASOUND IN MONITORING RESPONSE TO JAKi IN RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM A LONGITUDINAL STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1235-1236.	0.5	0
39	SAT0296â€¦SERUM LEPTIN LEVELS IN SYSTEMIC SCLEROSIS PATIENTS WITH ELECTROCARDIOGRAPHIC ABNORMALITIES. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1093.1-1093.	0.5	0
40	AB0170â€¦PHENOTYPIC CHARACTERIZATION OF ENDOTHELIAL PROGENITORS CELLS OF SYSTEMIC SCLEROSIS (SSC) PATIENTS: ROLE IN ENDOTHELIAL-TO-MESENCHYMAL TRANSITION PROCESS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1385.1-1385.	0.5	0
41	FRIO134â€¦EFFECT OF JAK INHIBITORS ON PAIN AND QUALITY OF LIFE IN RHEUMATOID ARTHRITIS PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 649.1-649.	0.5	2
42	FRIO121â€¦STEROID-SPARING EFFECT OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS FOLLOWED UP IN A REAL LIFE SETTING. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 641.2-642.	0.5	1
43	Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study. <i>Clinical Rheumatology</i> , 2019, 38, 3145-3151.	1.0	11
44	Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern". <i>Autoimmunity Reviews</i> , 2019, 18, 102394.	2.5	79
45	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.5	39
46	Nintedanib for Systemic Sclerosis-associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019, 380, 2518-2528.	18.9	1,025
47	CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon- γ production in systemic sclerosis. <i>Nature Communications</i> , 2019, 10, 1731.	5.8	90
48	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.5	79
49	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	2.9	75
50	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.5	142
51	Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement. <i>Cytokine</i> , 2019, 117, 41-49.	1.4	17
52	SAT0296â€¦FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
53	AB0220â€¦ALPHA- SMOOTH MUSCLE ACTIN EXPRESSION ON ENDOTHELIAL PROGENITORS CELLS OF SYSTEMIC SCLEROSIS PATIENTS: POSSIBLE ROLE IN THE ENDOTHELIAL-TO-MESENCHYMAL TRANSITION PROCESS. , 2019, , .		0
54	THU0020â€¦COMPARATIVE STUDY OF THE PHOSPHODIESTERASE TYPE 5 INHIBITOR SILDENAFIL AND THE PROSTACYCLIN ANALOGUE ILOPROST ON IP10 MODULATION IN SYSTEMIC SCLEROSIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	AB0688â€¦NEOPLASTIC RISK IN SYSTEMIC SCLEROSIS: A MONOCENTRIC STUDY. , 2019, , .		0
56	FRI0650â€¦A NAILFOLD CAPILLAROSCOPY STUDY IN A COHORT OF PATIENTS WITH ANTI-PHOSPHOLIPID ANTIBODIES. , 2019, , .		0
57	AB0389â€¦BIOSIMILAR ETANERCEPT VERSUS ORIGINATOR: RESULTS FROM A LONGITUDINAL PROSPECTIVE MONOCENTRIC STUDY. , 2019, , .		0
58	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1681-1685.	0.5	13
59	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	1.0	118
60	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e50-e50.	0.5	16
61	Nailfold capillaroscopy in systemic lupus erythematosus: A systematic review and critical appraisal. <i>Autoimmunity Reviews</i> , 2018, 17, 344-352.	2.5	84
62	Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2018, 57, 757-759.	0.9	60
63	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	0.9	60
64	Anti-aminoacyl-tRNA synthetase-related myositis and dermatomyositis: clues for differential diagnosis on muscle biopsy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 477-487.	1.4	9
65	OP0142â€¦Rituximab in systemic sclerosis : safety and efficacy data from the eustar network. , 2018, , .		1
66	Association of circulating CXCL10 and CXCL11 with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1845-1846.	0.5	34
67	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	2.9	15
68	<i>Porphyromonas gingivalis</i> in the tongue biofilm is associated with clinical outcome in rheumatoid arthritis patients. <i>Clinical and Experimental Immunology</i> , 2018, 194, 244-252.	1.1	24
69	Polymyalgia rheumatica and diverticular disease: just two distinct age-related disorders or more? Results from a case-control study. <i>Clinical Rheumatology</i> , 2018, 37, 2573-2577.	1.0	6
70	OP0091â€¦Cxcl10/cxcl11 serum measurement as potential predictor of systemic sclerosis. , 2018, , .		0
71	From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 82-87.	0.4	5
72	Potential role for the VDR agonist elocalcitol in metabolic control: Evidences in human skeletal muscle cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 167, 169-181.	1.2	26

#	ARTICLE	IF	CITATIONS
73	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	1.0	93
74	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.5	77
75	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
76	THU0006â€¦Trans-ethnic meta-analysis of genome-wide association studies identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. , 2017, , .		0
77	THU0252â€¦Nailfold capillaroscopy in systemic lupus erythematosus: a systematic review and critical appraisal. , 2017, , .		0
78	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.5	410
79	An international SURvey on non-invasive techniques to assess the microcirculation in patients with Raynaud's phenomenon (SUNSHINE survey). <i>Rheumatology International</i> , 2017, 37, 1879-1890.	1.5	33
80	FRI0045â€¦Oral microbiome profile in rheumatoid arthritis patients: association between tongue biofilm porphyromonas gingivalis amount and disease activity. , 2017, , .		0
81	AB0029â€¦Anti inflammatory effect of pde5 inhibition: scope for a new potential indication in ssc associated myositis. , 2017, , .		0
82	AB0030â€¦The effect of sildenafil and iloprost on cxcl10 level in systemic sclerosis: in vivo and in vitro comparison. , 2017, , .		0
83	THU0334â€¦Evaluation of subclinical vascular damage in patients with polymyalgia rheumatica: a cross-sectional study using an integrated, non-invasive approach of color doppler ultrasound and cardio-ankle vascular index (CAVI) measurement of arterial stiffness. , 2017, , .		0
84	SAT0347â€¦Disease modifying effect of iloprost in patients with systemic sclerosis and possible role of CXCL4 chemokine. , 2017, , .		0
85	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 169-182.	1.0	18
86	The role of dietary sodium intake on the modulation of T helper 17 cells and regulatory T cells in patients with rheumatoid arthritis and systemic lupus erythematosus. <i>PLoS ONE</i> , 2017, 12, e0184449.	1.1	43
87	â€œIn sickness and in healthâ€ the peculiar occurrence of polymyalgia rheumatica in married cohabiting couplesâ€”a case series and review of the literature. <i>Clinical Rheumatology</i> , 2016, 35, 1111-1115.	1.0	5
88	The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature. <i>Clinical Rheumatology</i> , 2016, 35, 1383-1388.	1.0	7
89	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.5	93
90	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.5	82

#	ARTICLE	IF	CITATIONS
91	AB0601â€¦Significant Cardiological Changes in Systemic Sclerosis: An Electrocardiographic and Echocardiographic Evaluation: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 1110.1-1110.	0.5	0
92	Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis. Annals of the Rheumatic Diseases, 2016, 75, 1743-1748.	0.5	68
93	AB0621â€¦From Vedoss To Established Systemic Sclerosis Diagnosis According To The New ACR/EULAR 2013 Classification Criteria: A French-Italian Capillaroscopic Survey. Annals of the Rheumatic Diseases, 2016, 75, 1116.2-1116.	0.5	3
94	Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Research and Therapy, 2016, 18, 276.	1.6	48
95	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2527-2539.	2.9	122
96	OP0031â€¦Risk Factors for Malignancies Synchronous To The Onset of Systemic Sclerosis in Patients Positive for Anti- RNA Polymerase III Antibodies: A Eustar Multicentre Study. Annals of the Rheumatic Diseases, 2016, 75, 64.2-64.	0.5	0
97	SAT0196â€¦Impress 2 (International Multicentric Prospective Study on Pregnancy in Systemic Sclerosis). Prospective, Case-Control Study of Pregnancy in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 739.1-739.	0.5	0
98	Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study. Journal of Rheumatology, 2016, 43, 995-996.	1.0	39
99	Digital ulcers predict a worse disease course in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 681-686.	0.5	111
100	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology, 2016, 55, 883-890.	0.9	121
101	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 2016, 75, 1285-1292.	0.5	56
102	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE, 2016, 11, e0163894.	1.1	158
103	Occupational therapy integrated with a self-administered stretching program on systemic sclerosis patients with hand involvement. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 157-161.	0.4	7
104	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 43-48.	0.4	1
105	Effects of rituximab in connective tissue disorders related interstitial lung disease. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 181-185.	0.4	20
106	AB0698â€¦MID-Term Effects of Rituximab in Connective Tissue Disorders Related Interstitial Lung Disease (ILD). Annals of the Rheumatic Diseases, 2015, 74, 1131.2-1131.	0.5	1
107	SAT0432â€¦Performance of the New EULAR/ACR 2013 Classification Criteria for Systemic Sclerosis in the Clinical Practice: A Single Center Experience. Annals of the Rheumatic Diseases, 2015, 74, 816.1-816.	0.5	0
108	OP0055â€¦Anti-RNA Polymerase III Antibodies in Patients with Systemic Sclerosis: A Eustar Multicenter Collaborative Study. Annals of the Rheumatic Diseases, 2015, 74, 88.1-88.	0.5	0

#	ARTICLE	IF	CITATIONS
109	AB0391â€¦Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1023.3-1024.	0.5	1
110	Identification of NF-Î²B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 71.	1.6	41
111	AB1086â€¦An Eular Study Group Pilot Study on Reliability of â€œSimpleâ€ Capillaroscopic Definitions to Describe Capillary Morphology in Rheumatic Diseases. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1263.3-1264.	0.5	0
112	AB0715â€¦Acute Stress: Is it a Risk Factor for the Development of Systemic Sclerosis??. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1137.2-1137.	0.5	1
113	AB0203â€¦Possible Role of Fractalkine/CX3CL1 (FKN) in the Microvascular Damage of Systemic Sclerosis (SSC). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 958.3-959.	0.5	0
114	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015, 54, 1262-1269.	0.9	25
115	FRI0042â€¦Anti-Carbamylated Protein Antibodies in Unaffected First-Degree Relatives of Rheumatoid Arthritis Patients: Lack of Correlation with Anti-Cyclic Citrullinated Protein Antibodies and Rheumatoid Factor. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 434.1-434.	0.5	1
116	Fetal programming and systemic sclerosis. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 839.e1-839.e8.	0.7	7
117	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1124-1131.	0.5	96
118	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	1.1	13
119	Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. <i>Clinical and Experimental Immunology</i> , 2015, 179, 300-308.	1.1	32
120	Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor Î² in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. <i>Reumatismo</i> , 2014, 66, 270-276.	0.4	17
121	The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. <i>Nature Communications</i> , 2014, 5, 5621.	5.8	427
122	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 99-105.	1.0	73
123	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.5	168
124	AB0624â€¦High Levels of Proinflammatory Biomarkers in Patients with Idiopathic Inflammatory Myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012.1-1012.	0.5	0
125	Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. <i>Arthritis Research and Therapy</i> , 2013, 15, R16.	1.6	60
126	<sc>IFN</sc>Î² therapy modulates <sc>B</sc> cell and monocyte crosstalk via <sc>TLR</sc>7 in multiple sclerosis patients. <i>European Journal of Immunology</i> , 2013, 43, 1963-1972.	1.6	23

#	ARTICLE	IF	CITATIONS
127	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	1.1	101
128	Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. <i>International Journal of Cardiology</i> , 2013, 167, 220-224.	0.8	12
129	Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. <i>Rheumatology</i> , 2013, 52, 1525-1528.	0.9	67
130	Brief Report: A Regulatory Variant in <i>CCR6</i> Is Associated With Susceptibility to Antitopoisomerase-Positive Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 3202-3208.	6.7	26
131	Nailfold Capillaroscopy for Prediction of Novel Future Severe Organ Involvement in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2013, 40, 2023-2028.	1.0	137
132	Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1217-1220.	0.5	160
133	SAT0398...Diagnostic value of anti mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: A multicentric study by firma group. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 607.1-607.	0.5	1
134	OPO225...Do worsening scleroderma capillaroscopic patterns predict novel future severe organ involvement in systemic sclerosis? A pilot study. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 131.3-132.	0.5	0
135	FRI0454...Hand function in systemic sclerosis: Effect of occupational therapy on the health status and quality of life. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 468.1-468.	0.5	0
136	The Vitamin D Receptor Agonist BXL-01-0029 as a Potential New Pharmacological Tool for the Treatment of Inflammatory Myopathies. <i>PLoS ONE</i> , 2013, 8, e77745.	1.1	19
137	FRI0242...Watermelon stomach in systemic sclerosis: A EUSTAR case-control study. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 396.1-396.	0.5	0
138	Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 31-6.	0.4	24
139	Evidence for Caveolin-1 (CAV1) as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A52.2-A53.	0.5	0
140	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1034-1041.	0.5	33
141	Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: An Italian multicentric study and review of the literature. <i>Autoimmunity Reviews</i> , 2012, 11, 815-820.	2.5	48
142	TGF β 2 receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1900-1903.	0.5	18
143	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012, 64, 1970-1977.	6.7	134
144	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the <i>TNFAIP3</i> locus as a risk factor for polyautoimmunity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2746-2752.	6.7	63

#	ARTICLE	IF	CITATIONS
145	“To Be or Not To Be,” Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 589-598.	1.6	126
146	<i>NLRP1</i> influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 668-674.	0.5	83
147	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1788-1792.	0.5	107
148	Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. <i>Rheumatology</i> , 2011, 50, 674-681.	0.9	23
149	Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA-Peptide Complexes in Systemic Lupus Erythematosus. <i>Science Translational Medicine</i> , 2011, 3, 73ra19.	5.8	1,080
150	Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 476-481.	0.5	330
151	High prevalence of capillary abnormalities in patients with diabetes and association with retinopathy. <i>Diabetic Medicine</i> , 2011, 28, 1039-1044.	1.2	49
152	Gender Disparity in Susceptibility to Oxidative Stress and Apoptosis Induced by Autoantibodies Specific to RLIP76 in Vascular Cells. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 2825-2836.	2.5	56
153	A genetic variation located in the promoter region of the <i>UPAR</i> (<i>CD87</i>) gene is associated with the vascular complications of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 247-256.	6.7	41
154	Association of the <i>CD226</i> Ser ³⁰⁷ variant with systemic sclerosis: Evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1097-1105.	6.7	49
155	Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: Association with the functional IRAK1 196Phe/532Ser haplotype. <i>Arthritis and Rheumatism</i> , 2011, 63, 3979-3987.	6.7	56
156	Multicentric evaluation of a second generation assay to detect antiviral citrullinated peptide antibodies: a collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni. <i>Journal of Clinical Pathology</i> , 2011, 64, 1139-1141.	1.0	6
157	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. <i>PLoS Genetics</i> , 2011, 7, e1002091.	1.5	205
158	Outcomes of Barrett’s oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. <i>Rheumatology</i> , 2011, 50, 1440-1444.	0.9	62
159	Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S46-52.	0.4	24
160	Association of a <i>KCNA5</i> gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. <i>Arthritis and Rheumatism</i> , 2010, 62, 3093-3100.	6.7	49
161	Anti-endothelial cell antibodies in rheumatic heart disease. <i>Clinical and Experimental Immunology</i> , 2010, 161, 570-575.	1.1	17
162	Nedd5, a novel autoantigen in systemic sclerosis: is it a marker of more severe disease?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 314-315.	0.5	1

#	ARTICLE	IF	CITATIONS
163	Potential adipokine involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A25-A25.	0.5	0
164	Successful Immunosuppressive Treatment of Dermatomyositis: A Nailfold Capillaroscopy Survey. <i>Journal of Rheumatology</i> , 2010, 37, 443-445.	1.0	10
165	Ultrasound Elastography Assessment of Skin Involvement in Systemic Sclerosis: Lights and Shadows. <i>Journal of Rheumatology</i> , 2010, 37, 1688-1691.	1.0	84
166	Association of the <i>TNFAIP3</i> rs5029939 variant with systemic sclerosis in the European Caucasian population. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1958-1964.	0.5	120
167	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.5	1,017
168	Oxidative stress parameters in different systemic rheumatic diseases. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 951-957.	1.2	54
169	Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 218-221.	0.5	214
170	Unifying abbreviations for biologics in rheumatology--does the idea hold promise?. <i>Rheumatology</i> , 2009, 48, 704-704.	0.9	3
171	Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 397-399.	0.5	98
172	Nailfold capillaroscopy abnormalities are associated with the presence of anti-endothelial cell antibodies in Sjogren's syndrome. <i>Rheumatology</i> , 2009, 48, 704-706.	0.9	6
173	EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 620-628.	0.5	559
174	Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis. <i>Clinical Rheumatology</i> , 2008, 27, 225-230.	1.0	21
175	Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients. <i>Journal of Clinical Laboratory Analysis</i> , 2008, 22, 210-215.	0.9	28
176	Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. <i>Joint Bone Spine</i> , 2008, 75, 87-89.	0.8	32
177	Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. <i>Joint Bone Spine</i> , 2008, 75, 29-33.	0.8	40
178	Anti-polymer antibodies are inversely correlated with pain and fatigue severity in patients with fibromyalgia syndrome. <i>Autoimmunity</i> , 2008, 41, 74-79.	1.2	9
179	Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 754-763.	0.5	739
180	Evaluation of Current Methods for the Measurement of Serum Anti Double-Stranded DNA Antibodies. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 401-406.	1.8	28

#	ARTICLE	IF	CITATIONS
181	Autonomic dysfunction and microvascular damage in systemic sclerosis. <i>Clinical Rheumatology</i> , 2007, 26, 1278-1283.	1.0	44
182	Anti-cyclic citrullinated peptide antibody determination in the synovial fluid of patients with rheumatoid arthritis: Comment on the article by Caspi et al. <i>Arthritis and Rheumatism</i> , 2006, 55, 681-682.	6.7	2
183	Parameters of oxidative stress status in healthy subjects: their correlations and stability after sample collection. <i>Journal of Clinical Laboratory Analysis</i> , 2006, 20, 139-148.	0.9	23
184	Nailfold capillaroscopy changes in systemic lupus erythematosus: correlations with disease activity and autoantibody profile. <i>Lupus</i> , 2005, 14, 521-525.	0.8	56
185	Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1241-1242.	0.5	9
186	Characterization and Recruitment of Plasmacytoid Dendritic Cells in Synovial Fluid and Tissue of Patients with Chronic Inflammatory Arthritis. <i>Journal of Immunology</i> , 2004, 173, 2815-2824.	0.4	135
187	Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. <i>Arthritis Research</i> , 2004, 6, R137.	2.0	104
188	Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. <i>Clinical Rheumatology</i> , 2003, 22, 102-106.	1.0	50
189	Relationship of Interleukin-12 and Interleukin-13 imbalance with class-specific rheumatoid factors and anticardiolipin antibodies in systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2003, 22, 107-111.	1.0	10
190	Anti-carbonic Anhydrase II Antibodies in Systemic Sclerosis: Association with Lung Involvement. <i>Autoimmunity</i> , 2003, 36, 85-89.	1.2	12
191	Adhesion molecule expression in the synovial membrane of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 569-570.	0.5	11
192	Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 174-176.	0.5	42
193	Co-occurrence of Psoriatic Arthritis with Collagenous Colitis: Clinicopathologic findings of a Case. <i>Clinical Rheumatology</i> , 2002, 21, 335-338.	1.0	17
194	Ultrasound Measurements at the Proximal Phalanges in Male Patients with Psoriatic Arthritis. <i>Osteoporosis International</i> , 2001, 12, 412-416.	1.3	8
195	Soluble Interleukin-2 Receptor in Sjogren's Syndrome: Relation to Main Serum Immunological and Immunohistochemical Parameters. <i>Clinical Rheumatology</i> , 2001, 20, 319-323.	1.0	11
196	Down-regulation of natural killer cells and of g/d T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity?. <i>Lupus</i> , 2000, 9, 333-337.	0.8	53
197	Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. <i>Lupus</i> , 2000, 9, 56-60.	0.8	22
198	Case definition of psoriatic arthritis. <i>Lancet</i> , The, 2000, 356, 2095-2096.	6.3	0

#	ARTICLE	IF	CITATIONS
199	Case definition of psoriatic arthritis. <i>Lancet, The</i> , 2000, 356, 2095.	6.3	19
200	Changes of Glycosylation of Serum Proteins in Sjogren's Syndrome: Correlation with Interleukin-6 and Soluble Interleukin-2 Receptor. <i>IUBMB Life</i> , 1999, 48, 385-390.	1.5	0
201	Changes of Glycosylation of Serum Proteins in Sjogren's Syndrome: Correlation with Interleukin-6 and Soluble Interleukin-2 Receptor. <i>IUBMB Life</i> , 1999, 48, 385-390.	1.5	0
202	Changes of glycosylation of serum proteins in psoriatic arthritis, studied by enzyme-linked lectin assay (ELLA), using concanavalin A. <i>IUBMB Life</i> , 1998, 46, 867-875.	1.5	3
203	Soluble interleukin-2 receptor and interleukin-6 levels: Evaluation during cyclosporin a and methotrexate treatment in psoriatic arthritis. <i>Clinical Rheumatology</i> , 1998, 17, 83-85.	1.0	3
204	Hepatitis C virus infection of salivary gland epithelial cells. <i>Journal of Hepatology</i> , 1997, 26, 1200-1206.	1.8	36
205	Ultrasound transmission velocity of the proximal phalanxes of the non-dominant hand in the study of osteoporosis. <i>Clinical Rheumatology</i> , 1997, 16, 396-403.	1.0	27
206	Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 1996, 15, 218-219.	1.0	3
207	Long-term follow-up of low-dose methotrexate therapy in one case of idiopathic retroperitoneal fibrosis. <i>Clinical Rheumatology</i> , 1995, 14, 481-484.	1.0	31
208	Lupus erythematosus panniculitis: An immunohistochemical study. <i>Clinical Rheumatology</i> , 1994, 13, 641-644.	1.0	9
209	One year treatment with low dose methotrexate in rheumatoid arthritis: Effect on class specific rheumatoid factors. <i>Clinical Rheumatology</i> , 1993, 12, 357-360.	1.0	22
210	Sternoclavicular joint disease in psoriatic arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1992, 51, 372-374.	0.5	25
211	Multiple cervical cord compressions in psoriatic arthritis. <i>Clinical Rheumatology</i> , 1992, 11, 51-54.	1.0	3
212	Avascular necrosis of the femoral head in long-term follow-up of systemic sclerosis: report of two cases. <i>Clinical Rheumatology</i> , 1989, 8, 386-392.	1.0	10
213	Hyperuricemia, Gout and Idiopathic Aseptic Necrosis of Bone. <i>Advances in Experimental Medicine and Biology</i> , 1989, 253A, 211-214.	0.8	3
214	Psychological Fragility in an Italian Cohort of Systemic Sclerosis Patients During COVID-19 Pandemic Category: Short Communication. <i>Open Access Rheumatology: Research and Reviews</i> , 0, Volume 14, 133-139.	0.8	0
215	Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	6